Research in IgG4-related disease (IgG4-RD) continues to advance - and with it, new hope for the IgG4-RD community around the world. 

In this IgG4ward! Fireside Chat, Dr. John H. Stone and Dr. Emmanuel Della Torre discuss key research highlights presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, one of the world's leading meetings for rheumatology research. Together, they explore some of the latest scientific developments that are helping shape the future of IgG4-related disease care. 

In this webinar

Join Dr. Stone and Dr. Della Torre as they discuss:

• Long-term findings from the landmark MITIGATE clinical trial

• New insights into how IgG4-RD disease flares may occur over time

• Highlights from the Phase 3 INDIGO clinical trial evaluating obexelimab

• How the treatment landscape for IgG4-RD continues to evolve

• Answers to questions submitted by patients and caregivers during the live Q&A

Designed for patients, caregivers, and healthcare professionals alike, this webinar translates complex research into meaningful, accessible education for the IgG4-RD community.

Viewing Guide:

Welcome and Foundation Updates

• Foundation news and upcoming educational programs

• Patient event updates

• IgG4ward! Academy

EULAR 2026 Research Highlights

• Long-term MITIGATE clinical trial updates

• New research on disease flare patterns

• Phase 3 INDIGO clinical trial overview

Live Patient Q&A

Hear Dr. Stone and Professor Della-Torre answer questions from patients and caregivers, including discussions on:

• Monitoring IgG4-RD

• Long-term treatment considerations

• Fatigue

• Fibrotic disease

• Clinical trials

• Future research

Medical Disclaimer: This webinar is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with questions about your individual medical care.